The Boston Scientific WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device has received the Prix Galien USA 2018 Award for Best Medical Technology. Counted among the global health innovation industry’s most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition. The WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device is a first-of-its-kind, proven alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.
The Prix Galien Foundation recognizes and rewards excellence, novelty, humanitarian benefit, and entrepreneurship in the life sciences. The Prix Galien USA awards three prizes for therapeutics, including Best Pharmaceutical Agent, Best Biotechnology Product and Best Medical Technology approved by the FDA in the past five years. Awards were presented at the American Museum of Natural History in New York on October 25.
Tim Ley, Research & Design Manager, Interventional Cardiology, and Danielle Lippmann, Regulatory Affairs Specialist for WATCHMAN™, accepted the award on behalf of Boston Scientific.
Thank you to our Interventional Cardiology team, whose hard work has made this award possible.
For more information about the WATCHMAN™ Left Atrial Appendage Closure Device, click here.
The Boston Scientific SpyGlass™ DS Direct Visualization System and the AXIOS™ Stent and Electrocautery Enhanced Delivery System were also nominated for the Best Medical Technology award. Past nominations for Best Medical Technology include the Alair™ System and the S-ICD System, with the S-ICD System winning the award in 2013. This is the third year of consideration for both SpyGlass™ and WATCHMAN™, and the first year AXIOS™.
For more on the Galien Foundation and the awards, click here.